Amit G. Singal, Jasmin A. Tiro, Caitlin C. Murphy, Jorge A. Marrero, Katharine McCallister, Hannah Fullington, Caroline Mejias, Akbar K. Waljee, Wendy Pechero Bishop, Noel O. Santini, Ethan A. Halm – 2 August 2018 – Hepatocellular carcinoma (HCC) surveillance is associated with early tumor detection and improved survival in patients with cirrhosis; however, effectiveness is limited by underuse. We compared the effectiveness of mailed outreach and patient navigation strategies to increase HCC surveillance in a racially diverse cohort of patients with cirrhosis.

Yang Shen, Mark J. Czaja – 2 August 2018

Zobair M. Younossi – 2 August 2018 – Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) can progress to cirrhosis, hepatocellular carcinoma (HCC), death, or liver transplantation. NASH has also been associated with impaired health‐related quality of life and poses a significant economic burden.

Thomas Greuter, Vijay H. Shah – 2 August 2018

Keisaku Sato, Marco Marzioni, Fanyin Meng, Heather Francis, Shannon Glaser, Gianfranco Alpini – 2 August 2018 – Ductular reaction (DR) is characterized by the proliferation of reactive bile ducts induced by liver injuries. DR is pathologically recognized as bile duct hyperplasia and is commonly observed in biliary disorders. It can also be identified in various liver disorders including nonalcoholic fatty liver disease. DR is associated with liver fibrosis and damage, and the extent of DR parallels to patient mortality.

Karen F. Murray, William F. Balistreri, Sanjay Bansal, Suzanne Whitworth, Helen M. Evans, Regino P. Gonzalez‐Peralta, Jessica Wen, Benedetta Massetto, Kathryn Kersey, Jiang Shao, Kimberly L. Garrison, Bandita Parhy, Diana M. Brainard, Ronen Arnon, Lynette A. Gillis, Maureen M. Jonas, Chuan‐Hao Lin, Michael R. Narkewicz, Kathleen Schwarz, Philip Rosenthal – 2 August 2018 – Currently, there are no interferon‐free treatments available for hepatitis C virus (HCV)–infected patients younger than 12 years.

Manuel Tufoni, Carmen Serena Ricci, Giacomo Zaccherini – 2 August 2018

Antoine L’Hermitte, Sandrine Pham, Mathilde Cadoux, Gabrielle Couchy, Stefano Caruso, Marie Anson, Anne‐Marie Crain‐Denoyelle, Séverine Celton‐Morizur, Satoshi Yamagoe, Jessica Zucman‐Rossi, Chantal Desdouets, Jean‐Pierre Couty – 2 August 2018 – Leukocyte cell‐derived chemotaxin‐2 (LECT2) was originally identified as a hepatocyte‐secreted chemokine‐like factor and a positive target of β‐catenin signaling. Here, we dissected out the mechanisms by which LECT2 modulates hepatocellular carcinoma (HCC) development using both HCC mouse models and human HCC samples.

Wolfgang Stremmel – 2 August 2018

Kimberly A. Forde, Michael B. Fallon, Michael J. Krowka, Michael Sprys, David S. Goldberg, Karen L. Krok, Mamta Patel, Grace Lin, Jae K. Oh, Carl D. Mottram, Paul D. Scanlon, Steven M. Kawut, for the Pulmonary Vascular Complications of Liver Disease 2 Study Group – 2 August 2018 – Screening for hepatopulmonary syndrome (HPS) using pulse oximetry is recommended in liver transplant (LT) candidates because mortality is increased, independently of the severity of the oxygenation defect. LT exception points may be afforded to those with HPS and severe hypoxemia.